IC Disease

While this clinical trial is not currently open for enrollment, keep your eyes open for future news on researchers looking for study participants.  This clinical trial (ClinicalTrials.gov Identifier: NCT00823030) is to determine the amount of improvement in bladder function and pain relief with the administration of 2% alkalinized lidocaine in IC Disease patients.

Once researchers start actively recruiting IC Disease patients, they would like to have approximately 40 patients to properly complete their clincial trial.  This trial is sponsored by the North Shore Long Island Jewish Health System.

Inclusion Criteria:

• Male & female patients ages 18 - 80
• Must have a clinical diagnosis of IC Disease based on the National Institute of Diabetes, Digestive and Kidney Diseases (NIDKK) criteria.
• Written informed consent
• Able to understand and complete a VAS/GRA/modified IPSS assessment

Exclusion Criteria:

• Having a severely disabling concurrent medical condition
• A history of pelvic radiation therapy, tuberculous cystitis, neurologic disease affecting bladder function, bladder cancer, or carcinoma in situ, or urethral cancer
• Evidence of urethritis
• An allergy to lidocaine

Contact Information:

For further information on this clinical trial and to find out when researchers will be recruiting patients, contact:

• Amin S Herati, BA
  516-734-8570
  aherati@gmail.com